Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma
Advances in the Treatment of Patients with Multiple Myeloma
For treatment of newly diagnosed multiple myeloma (MM) the objective in therapy is to obtain deep response after primary therapy by choosing the appropriate regimen in both transplant and non-transplant patients. In situations with no definite data on therapeutic choices, participation in clinical trials should be encouraged. In addition, a uniform treatment approach cannot be applied to all patients. Recognizing that 20-50% of the patients with MM have kidney disease, understanding the clinical features, evaluation, diagnosis and treatment of kidney disease in patients with multiple myeloma is important.
For relapsed refractory MM, the choice of appropriate therapy for a patient would depend on the context of clinical relapse such as prior treatment and duration of response. New regimens have been included as options for treatment of relapsed/refractory MM. Many factors are considered before choosing the optimal therapy for relapsed/refractory MM (e.g., previous lines of therapy). In MM, even if the patients have been exposed to drug classes previously, different agents within these respective classes can be rationally used. Other factors taken into consideration would be refractoriness to a specific class of drugs, impact of age on treatment strategy etc. Clinicians must understand the treatment evolution and guidelines for administration of available therapies in the context of the patient's therapeutic and disease history to navigation through the complex treatment landscape.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Select appropriate evidence-based strategies for management of patients with newly diagnosed multiple myeloma taking individual patient characteristics into consideration.
- Evaluate clinical data supporting the current treatment options for patients with relapsed/refractory multiple myeloma.
- Discuss supportive care measures needed for disease- and treatment-related symptoms and outline strategies to manage them.
Yvonne A. Efebera, MD, MPH
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Barry A. Hammer, PA-C, MPAS
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Barry A. Hammer, PA-C, MPAS
The faculty listed below discloses the following relevant financial relationships:
Yvonne A. Efebera, MD, MPH
Akcea Therapeutics: Scientific Advisor
Janssen Pharmaceutica Products, LP: Honoraria
Takeda Pharmaceuticals North America, Inc.: Honoraria
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-073-L01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00045283; Approval #: 210000651
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Price
This webinar was presented live one time only on Wednesday, March 3, 2021, from 3:30 – 4:30 PM EST (UTC -5).
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing